Skip to main content

Table 1 Clinical characteristics of the study subjects

From: Correlation of PMN elastase and PMN elastase-to-neutrophil ratio with disease activity in patients with myositis

 IIMsDMPMSLESScRA
Number745816202020
Gender (female/male)55/1941/1714/217/312/818/2
Age (years)50 (20–75)50 (20–75)51 (32–69)41 (14–62)57 (14–73)58 (44–70)
Disease durations (years)0.8 (0.1–12)0.8 (0.1–12)0.7 (0.1–4)3.5 (0.1–15)2 (0.7–7)1 (0.1–10)
Active/remission (number)44/3035/239/710/1010/1010/10
MYOACT1.4 (0.7–4.2)1.4 (0.7–4.2)1.4 (0.7–2.6)
Muscle enzymes
 CK, uKat/L59 (12.5–6621)58 (12.5–6621)65.1 (21.3–5890.8)
 AST, uKat/L30.8 (11.2–420.1)30.8 (12.4–420.1)29.8 (11.2–227.6)21.7 (13.5–68.9)25.1 (13.5–66.3)17.3 (9.6–45.2)
 ALT, uKat/L29.9 (6.2–201.8)31.7 (10.4–201.8)25.7 (6.2–139)19 (9.6–152.2)14.3 (3.6–72.3)13.4 (4.9–59.9)
 LDH, uKat/L284 (137–1267)282.5 (141–1267)286 (137–767)
Inflammation marker
 CRP, mg/L3.2 (1–165)3.8 (1.1–165)2.5 (1–7.1)5.1 (1.3–242)4.1 (1–43.2)14.1 (1.5–86.5)
 ESR, mm/h49 (4–120)53 (4–120)30 (6–85)55 (2–120)54.5 (2–114)92.5 (33–120)
 C4, mg/L203.5 (39.6–454)222 (39.6–454)185 (102–437)153 (23.2–365)188 (108–375)208 (117–318)
 C3, mg/L836 (415–1690)826 (415–1690)803 (566–955)704 (81–1210)795 (411–1410)1010 (817–1220)
 Neutrophil, × 109/L4.5 (1.4–15.1)5.2 (1.4–12.4)4.7 (1.5–15.1)4.8 (0.7–11.8)4.4 (1.8–11.5)4.5 (1.9–8.6)
 Lymphocyte, × 109/L1.4 (0.1–4.1)1.3 (0.1–4.1)1.4 (0.3–3.7)1.4 (0.1–2.8)1.3 (0.6–2.6)1.6 (0.9–3.1)
 NLR3.7 (0.7–23)4.4 (1.3–23)3.9 (0.8–14)3.6 (1.2–31)3.3 (2.1–11.5)3.0 (1.4–7.9)
  1. Data are presented as number of patients or median (min–max)
  2. MYOACT myositis disease activity assessment, CK creatine phosphokinase, AST aspartate aminotransferase, ALT alanine aminotransferase, LD lactate dehydrogenase, CRP C-reactive protein, ESR erythrocyte sedimentation rate, C4 complement fraction 4, C3 complement fraction 3, NLR the ratio of neutrophil count to lymphocyte count